Internal Medicine, Pulmonary Disease · Manchester, NH
NPI
1881836914
Since 2009
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
4
Medicare group memberships
Hospitals
4
Hospital affiliations
87 McGregor St
Manchester, NH, 03102
Phone (603) 695-2500
Groups this clinician bills Medicare through
Medicare paid, 2024
$47K
1,134 services
Medicare patients, 2024
514
Average age 75
Drug cost, 2024
$1.7M
2,912 prescriptions
Company payments, 2023
$79.71
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Richard N Read was code 99214 (office e&m - established), 270 times for 209 patients. In total Richard N Read billed 1,134 services in 36 codes, and Medicare paid $47K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-02-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 270 | 209 | $67.95 | $18K |
| 94729 Pulmonary Function Testing | Facility | 156 | 154 | $6.32 | $986 |
| 94726 Pulmonary Function Testing | Facility | 146 | 144 | $8.53 | $1,245 |
| 94060 Pulmonary Function Testing | Facility | 127 | 126 | $7.35 | $933 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 93 | 89 | $12.73 | $1,184 |
| 94010 Pulmonary Function Testing | Facility | 67 | 65 | $5.62 | $377 |
| 99291 Critical Care E&M | Facility | 60 | 24 | $156.19 | $9,371 |
| 99213 Office E&M - Established | Office | 57 | 57 | $46.58 | $2,655 |
| 99204 Office E&M - New | Office | 29 | 29 | $81.62 | $2,367 |
| 99215 Office E&M - Established | Office | 29 | 25 | $104.59 | $3,033 |
| 99232 Hospital E&M - Subsequent | Facility | 23 | 16 | $60.93 | $1,401 |
| 99233 Hospital E&M - Subsequent | Facility | 13 | 12 | $91.85 | $1,194 |
By year: 2022 $96K for 1,290 services; 2023 $66K for 1,139 services; 2024 $47K for 1,134 services.
Medicare prescription drug claims, 2024
In 2024, the drug Richard N Read prescribed most often to Medicare patients was Albuterol Sulfate Hfa (Albuterol Sulfate), with 432 prescriptions and refills. In total Richard N Read wrote 2,912 Medicare prescriptions that cost $1.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Albuterol Sulfate Hfa Albuterol Sulfate | 432 | 539 | 140 | $12K |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 251 | 325 | 63 | $202K |
| Breo Ellipta Fluticasone/Vilanterol | 203 | 261 | 45 | $101K |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 150 | 223 | 44 | $16K |
| Incruse Ellipta Umeclidinium Bromide | 146 | 210 | 34 | $71K |
| Wixela Inhub Fluticasone Propion/Salmeterol | 125 | 156 | 42 | $12K |
| Montelukast Sodium Generic | 120 | 263 | 41 | $1,266 |
| Advair Hfa Fluticasone Propion/Salmeterol | 116 | 134 | 28 | $47K |
| Prednisone Generic | 103 | 129 | 52 | $345 |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 98 | 112 | 23 | $50K |
| Spiriva Handihaler Tiotropium Bromide | 85 | 123 | 22 | $60K |
| Symbicort Budesonide/Formoterol Fumarate | 70 | 94 | 17 | $21K |
| Arnuity Ellipta Fluticasone Furoate | 66 | 70 | 12 | $17K |
| Spiriva Respimat Tiotropium Bromide | 62 | 82 | 15 | $42K |
| Combivent Respimat Ipratropium/Albuterol Sulfate | 61 | 67 | 14 | $33K |
Brand drugs: 1,870 claims; generic drugs: 1,042 claims.
Money and other things of value reported by the companies
In 2023, drug and medical device companies paid Richard N Read $79.71 ($79.71 in general payments such as food, travel and fees) from 1 company. The largest payer was Intuitive Surgical, Inc. with $79.71.
| Company | Payments | Amount |
|---|---|---|
| Intuitive Surgical, Inc. ISRG | 1 | $79.71 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.